Boehringer Ingelheim International Gmbh

Boehringer Ingelheim Vetmedica Gmbh

Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharma Gmbh & Co Kg

Klaus Bornemann

Klaus Klinder

Cornelia Dorner-Ciossek

Marcus Kostka

Bernd Beck

Frank Sams-Dodd

Dagmar Kugler

Guenter Trummlitz

Frank Himmelsbach

Hans Briem

Klaus Fuchs

Edward S Lazer

Clara K Miao

Katja Fechteler

Cornelia Dorner-Clossek

Markus Kostka

A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid &#x3b2; peptides (A&#x3b2;) and/or with a changed ratio of levels of A&#x3b2; isoforms and/or with the formation of plaques containing amyloid &#x3b2; peptide (A&#x3b2;) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R, R, R, R, L1 and i are defined as in claim

Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds

Method of treating diseases and conditions associated with an altered level of amyloid &#x3b2; peptides and new enolcarboxamide compounds

Method of treating diseases and conditions associated with an altered level of amyloid &#x3b2;  peptides and new enolcarboxamide compounds

The present invention relates to trisubstituted pyrimidines of formula whereinRto Rare defined as in claim 1, which are suitable for the treatment of illnesses in which &#x3b2;-amyloid modulators have a therapeutic benefit, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Trisubstituted pyrimidines

Growing community of inventors

Setzingen, Germany

Klaus Bornemann